A rational strategy to support approved COVID-19 vaccines prioritization.
Hum Vaccin Immunother
; 17(10): 3474-3477, 2021 Oct 03.
Article
em En
| MEDLINE
| ID: mdl-34114939
The World Health Organization (WHO) proposed a set of criteria to be considered for the prioritization of COVID-19 candidate vaccines for further development of phase II/III clinical trials, thinking in a target audience that includes vaccine scientists, product developers, manufacturers, regulators, and funding agencies. In this paper, a knowledge-based or rational strategy is employed to perform a prioritization matrix of approved COVID-19 vaccines: BBIBP-CorV, JANSSEN, CORONAVAC, SPUTNIK V, MODERNA, PFIZER, and VAXZEVRIA, based on those proposed criteria by WHO, related to safety, efficacy, stability, implementation, and availability. We found that JANSSEN vaccine is the one with the highest score in the present study, but our analysis suggests that the WHO criteria could be more useful if they are considered separately, taking into account the social, demographic and economic characteristics of each country.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas contra COVID-19
/
COVID-19
Limite:
Humans
Idioma:
En
Revista:
Hum Vaccin Immunother
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Colômbia
País de publicação:
Estados Unidos